PSMA-1007

Phase 3Small molecule

AABX advanced biochemical compounds GmbH

PSMA-1007 is one of 36 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerRecruiting

Magnetic Resonance ImagingCompleted

Prostate CancerPhase 3

Recruiting

Magnetic Resonance ImagingPreclinical

Completed

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Docetaxel /m²

AstraZeneca

Phase 3

2 2

PSMA-1007

AABX advanced biochemical compounds GmbH

Phase 3

3 3

Piflufolastat F 18

Novartis

Phase 3

1 4

Fuzuloparib

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 5

INR101

YYunhe Pharmaceutical (Tianjin) Co., Ltd

Phase 3

3 6

Trexall

Jazz Pharmaceuticals

Preclinical

—7

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 8

Duragesic

CCephalon

Preclinical

1 9

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Prostate Cancer

NCT06122584

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Completed·AABX advanced biochemical compounds GmbH·Phase 3·NCT04742361·136 enrolled

Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Recruiting·AABX advanced biochemical compounds GmbH·Phase 3·NCT06122584·434 enrolled

Multi-modality Prostate Cancer Image Guided Interventions - 5

Completed·GGlenn Bauman·Phase 2·NCT04053842·16 enrolled

Magnetic Resonance Imaging1 trial

Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA

Completed·IIrene Burger·N/A·NCT03187990·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for PSMA-1007. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PSMA-1007 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PSMA-1007. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ABX advanced biochemical compounds GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AABX advanced biochemical compounds GmbH

PSMA-1007

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Prostate Cancer3 trials

Magnetic Resonance Imaging1 trial

References

Drug Info

Quick Facts

Related News